DLA Piper represented Osceola Capital, a middle-market private equity firm focused on services businesses, in the recapitalization of Central Medical Group, a New Jersey-based provider of outsourced equipment management solutions for hospices.
Central Medical Group represents the sixth platform in Osceola's current fund and Osceola's second healthcare platform investment in 2020. DLA Piper also represented Osceola in its investment in Healthcents, a leading provider of medical reimbursement and related services, in January.
“We were pleased to once again partner with Osceola to assist with its recapitalization of Central Medical,” said Brian Gordon, the DLA Piper partner who led the firm’s deal team. “Our extensive healthcare private equity experience was an important factor in our handling of this transaction, which will position Osceola well for continued success.”
In addition to Gordon (Atlanta), the DLA Piper deal team representing Osceola Capital included partners Ryan Moreno (New York), Russell Sass (Miami), Jamie Konn, Anna Spencer (both of Atlanta), Julia Kovacs (Washington, DC), William Bartow (Philadelphia) and Stacy Paz (Silicon Valley); of counsel Andrew Much (Atlanta); attorneys Bradley Verona and Hunter Street (both of Atlanta); and associates Andrew Wolfe (New York), Julia Zaft (Miami), Sydney Hu (Atlanta), Mary Claire Blythe (Baltimore), Emily Maus (Washington, DC) and Priya Narahari (Philadelphia).
DLA Piper’s Private Equity practice includes more than 100 US lawyers who provide strategic counsel to private equity funds and the industry-leading companies they invest in. In 2019, Pitchbook recognized DLA Piper as the second most active private equity law firm globally, further solidifying the strength of the firm’s team and its depth of experience executing private equity transactions.
The firm's global Healthcare sector consists of a multidisciplinary legal team with niche experience in health-related business and legal issues. The team regularly works with corporations and financial institutions, private investors, private equity groups, venture capital funds, institutional investors and portfolio companies in all types of healthcare transactions.
